13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001615982
Total reported value
$3.3B
$3.3B
31 檔
22.8%
According to the latest 13F quarterly dataset, Venrock Adviser, LLC managed an equity portfolio of $3.3B at the end of Q2 2025, spanning 31 distinct U.S. exchange-listed positions.
In Q2 2025, Venrock Adviser, LLC adopted a defensive or profit-taking posture, trimming 6 positions and completely liquidating 10 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | Stock-Other | 27.64% | +7.50% | — | |
| 2 | OCUL | Ocular Therapeutix Inc | Stock-Other | 8.88% | -0.19% | — | |
| 3 | ✓ | Stock-Other | 8.00% | — | — | ||
| 4 | ELVN | Enliven Therapeutics Inc | Stock-Other | 6.05% | -1.72% | — | |
| 5 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 5.70% | -4.86% | EXIT | |
| 6 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 5.02% | -0.62% | +107.28% | |
| 7 | VRDN | Viridian Therapeutics Inc | Stock-Other | 4.07% | -1.02% | — | |
| 8 | ORKA | Oruka Therapeutics Inc | Stock-Other | 3.48% | +4.37% | — | |
| 9 | SYRE | Spyre Therapeutics Inc | Stock-Other | 3.01% | +1.10% | — | |
| 10 | PHVS | Pharvaris N.V. | Stock-Other | 2.70% | — | -34.22% | |
| 11 | COGT | Cogent Biosciences Inc | Stock-Other | 2.56% | -0.94% | -16.34% | |
| 12 | JBIO | Jade Biosciences Inc | Stock-Other | 2.41% | +0.48% | — | |
| 13 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 2.38% | -1.18% | — | |
| 14 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.33% | — | -39.22% | |
| 15 | UPB | Upstream Bio Inc | Stock-Other | 1.89% | — | — | |
| 16 | ERAS | Erasca Inc | Stock-Other | 1.70% | +0.05% | +10.12% | |
| 17 | ✓ | Crescent Biopharma Inc. | Stock-Other | 1.68% | -0.30% | — | |
| 18 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.55% | -0.01% | — | |
| 19 | SVRA | Savara Inc | Stock-Other | 1.52% | -0.05% | +172.72% | |
| 20 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.40% | -0.21% | -42.67% | |
| 21 | ✓ | Engene Holdings Inc | Stock-Other | 1.38% | -1.21% | EXIT | |
| 22 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.99% | — | — | |
| 23 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.78% | +0.03% | — | |
| 24 | ABVX | Abivax Sa-adr | Stock-Other | 0.77% | — | — | |
| 25 | ✓ | Stock-Other | 0.60% | — | — | ||
| 26 | SEPN | Septerna Inc | Stock-Other | 0.43% | -0.45% | EXIT | |
| 27 | SRZN | Surrozen Inc | Stock-Other | 0.42% | -0.19% | — | |
| 28 | ✓ | Zura Bio LTD | Stock-Other | 0.36% | -0.28% | -7.80% | |
| 29 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.18% | +0.21% | — | |
| 30 | ✓ | Casi Pharmaceuticals Inc | Stock-Other | 0.09% | — | — | |
| 31 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.04% | -1.00% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ORIC | Oric Pharmaceuticals Inc | +3.5% | +107.28% | Add |
| 2 | JBIO | Jade Biosciences Inc | +2.4% | NEW | New buy |
| 3 | CTMX | Cytomx Therapeutics Inc | +2.4% | NEW | New buy |
| 4 | ✓ | Crescent Biopharma Inc. | +1.7% | NEW | New buy |
| 5 | OCUL | Ocular Therapeutix Inc | +0.9% | — | Unchanged |
| 6 | SVRA | Savara Inc | +0.8% | +172.72% | Add |
| 7 | UPB | Upstream Bio Inc | +0.7% | — | Unchanged |
| 8 | APGE | Apogee Therapeutics Inc | +0.6% | — | Unchanged |
| 9 | SEPN | Septerna Inc | +0.4% | NEW | New buy |
| 10 | CDTX | Cidara Therapeutics Inc | +0.4% | -39.22% | Trim |
| 11 | ABVX | Abivax Sa-adr | +0.1% | — | Unchanged |
| 12 | GLYCEUR | Glycomimetics Inc | -0.1% | EXIT | Sold out |
| 13 | TIL | Instil Bio Inc | -0.1% | EXIT | Sold out |
| 14 | ✓ | -0.1% | — | Unchanged | |
| 15 | TNYA | Tenaya Therapeutics Inc | -0.1% | EXIT | Sold out |
| 16 | TENX | Tenax Therapeutics Inc | -0.1% | -52.69% | Trim |
| 17 | ✓ | Casi Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 18 | ✓ | Mersana Therapeutics Inc | -0.1% | EXIT | Sold out |
| 19 | IPSC | Century Therapeutics Inc | -0.1% | EXIT | Sold out |
| 20 | CGEM | Cullinan Therapeutics Inc | -0.1% | — | Unchanged |
| 21 | CATBUSD | Astria Therapeutics Inc | -0.1% | — | Unchanged |
| 22 | ORKA | Oruka Therapeutics Inc | -0.1% | — | Unchanged |
| 23 | FDMT | 4d Molecular Therapeutics In | -0.2% | EXIT | Sold out |
| 24 | ✓ | Zura Bio LTD | -0.2% | -7.80% | Trim |
| 25 | ERAS | Erasca Inc | -0.2% | +10.12% | Add |
| 26 | SRZN | Surrozen Inc | -0.2% | — | Unchanged |
| 27 | APLT | Applied Therapeutics Inc | -0.2% | EXIT | Sold out |
| 28 | ARTV | Artiva Biotherapeutics Inc | -0.2% | — | Unchanged |
| 29 | TRVI | Trevi Therapeutics Inc | -0.3% | EXIT | Sold out |
| 30 | COGT | Cogent Biosciences Inc | -0.3% | -16.34% | Trim |
| 31 | DYN | Dyne Therapeutics Inc | -0.4% | — | Unchanged |
| 32 | VRDN | Viridian Therapeutics Inc | -0.4% | — | Unchanged |
| 33 | ✓ | Engene Holdings Inc | -0.5% | — | Unchanged |
| 34 | SYRE | Spyre Therapeutics Inc | -0.7% | — | Unchanged |
| 35 | ✓ | -0.7% | — | Unchanged | |
| 36 | ELVN | Enliven Therapeutics Inc | -0.7% | — | Unchanged |
| 37 | SLDB | Solid Biosciences Inc | -0.8% | EXIT | Sold out |
| 38 | 4XC1 | Kalvista Pharmaceuticals Inc | -0.9% | +0.37% | Add |
| 39 | DNTH | Dianthus Therapeutics Inc | -1.3% | -42.67% | Trim |
| 40 | PHVS | Pharvaris N.V. | -1.5% | -34.22% | Trim |
| 41 | PRAX | Praxis Precision Medicines I | -3.2% | EXIT | Sold out |
According to official SEC Form 13F filings, Venrock Adviser, LLC reported a total U.S. public equity portfolio value of $3.3B across 31 disclosed positions in Q2 2025.
During Q2 2025, Venrock Adviser, LLC's top holdings by market value included APGE (27.6%)、OCUL (8.9%)、 (8.0%). The largest single position, APGE, represented 27.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including APGE, OCUL, ) accounted for 22.8% of total reported equity market value during Q2 2025.
Top New Position Initiated
JBIO
市值: $32.2M
Top Position Liquidated / Trimmed
PRAX
前期市值: $37.5M
In Q2 2025, Venrock Adviser, LLC made 24 total portfolio adjustments, initiating 4 new buys, adding to 4 positions, trimming 6 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.